What Definium Therapeutics Inc's executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 0 | 0 |
| Sells | 6 | 17 |
| Total trades | 19 | 46 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 2,030,215 | 3,579,600 |
| Disposed | 81,951 | 225,900 |
| Net activity | +1,948,264 | +3,353,700 |
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Barrow Robert | Chief Executive Officer | Sep 25 | Open-market sale · S | −31,550 | $36.57 | −$1.15M | 2,213,090 |
| Karlin Dan | Chief Medical Officer | Sep 25 | Open-market sale · S | −10,853 | $36.57 | −$397K | 792,846 |
| Roberts Brandi | Chief Financial Officer | Sep 25 | Open-market sale · S | −3,377 | $36.57 | −$123K | 394,528 |
| Sullivan Mark | Chief Legal Officer | Sep 25 | Open-market sale · S | −14,051 | $36.57 | −$514K | 494,228 |
| Wiley Matthew T. | Chief Commercial Officer | Sep 25 | Open-market sale · S | −3,097 | $36.57 | −$113K | 359,036 |
| Vallone Carol A | Director | Sep 18 | Exercise / conversion · M | +1,086 | $35.52 | +$38.6K | 22,296 |
| Krebs Andreas | Director | Sep 18 | Exercise / conversion · M | +1,629 | $35.52 | +$57.9K | 21,402 |
| Wiley Matthew T. | Chief Commercial Officer | Sep 14 | Grant / award · A | +125,000 | — | — | 362,133 |
| Barrow Robert | Chief Executive Officer | Sep 14 | Grant / award · A | +750,000 | — | — | 2,244,640 |
| Roberts Brandi | Chief Financial Officer | Sep 14 | Grant / award · A | +125,000 | — | — | 397,905 |
| Sullivan Mark | Chief Legal Officer | Sep 14 | Grant / award · A | +125,000 | — | — | 508,279 |
| Karlin Dan | Chief Medical Officer | Sep 14 | Grant / award · A | +200,000 | — | — | 803,699 |
| Barrow Robert | Chief Executive Officer | Sep 03 | Open-market sale · S | −19,023 | $37.94 | −$722K | 1,494,640 |
| Barrow Robert | Chief Executive Officer | Sep 02 | Grant / award · A | +40,000 | — | — | 1,513,663 |
| Wiley Matthew T. | Chief Commercial Officer | Aug 12 | Grant / award · A | +62,500 | — | — | 237,133 |
| Roberts Brandi | Chief Financial Officer | Aug 12 | Grant / award · A | +62,500 | — | — | 271,987 |
| Karlin Dan | Chief Medical Officer | Aug 12 | Grant / award · A | +100,000 | — | — | 603,282 |
| Barrow Robert | Chief Executive Officer | Aug 12 | Grant / award · A | +375,000 | — | — | 1,473,246 |
| Sullivan Mark | Chief Legal Officer | Aug 12 | Grant / award · A | +62,500 | — | — | 383,071 |
| Wiley Matthew T. | Chief Commercial Officer | Jun 25 | Open-market sale · S | −2,867 | $45.03 | −$129K | 174,633 |
Loading...
